GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • Watch a surgeon tattoo this man's eyeball

    A Harvard-trained eye surgeon demonstrates how to perform a corneal tattoo on a man with one blind, milky-white eye. It's a merging of medicine and body art that will help restore confidence and quality of life.

  • LONDON, July 2- China will receive cut-price supplies of GlaxoSmithKline's new HIV drug Tivicay, following a deal for Shanghai- based Desano Pharmaceuticals to become an additional manufacturer of the medicine's active ingredient. The collaboration between GSK's HIV unit ViiV Healthcare and Desano marks an improvement in the business climate for the...

  • A cure for cancer? Wednesday, 1 Jul 2015 | 2:49 PM ET
    A cure for cancer?

    One of the world's leading cancer geneticist says its possible a cure for cancer will be found within the next 10 years, thanks to technology by Juno Therapeutics. Dr. Gary Gilliland of Fred Hutch Cancer Research, launched Juno in 2013.

  • NEW YORK, July 1- Two years after New York socialite Brooke Astor died in 2007, her son, Anthony Marshall, was convicted of bilking her of millions of dollars. Three states, most recently Missouri, have enacted laws that allow retail brokers to help curb scams against people with dementia. More than five million Americans over the age of 65 have Alzheimer's disease,...

  • NEW YORK, July 1- Two years after New York socialite Brooke Astor died in 2007, her son, Anthony Marshall, was convicted of bilking her of millions of dollars. Three states, most recently Missouri, have enacted laws that allow retail brokers to help curb scams against people with dementia. More than five million Americans over the age of 65 have Alzheimer's disease,...

  • ZURICH, June 30- A drug being developed by Roche to treat multiple sclerosis met its main targets in two final-stage clinical trials, boosting the Swiss company's hopes of expanding beyond its core cancer business. Rebif, made by Germany's Merck KGaA, is already battling stiff competition from a new generation of oral drugs against the debilitating disease.

  • June 29- Celgene Corp said it would invest about $1 billion in Juno Therapeutics Inc to partner in the development and marketing of immunotherapies for the treatment of cancer and autoimmune diseases. Celgene will pay Juno about $150 million upfront and buy about 10 percent of Juno's shares at $93 each, almost double of Juno's closing price on Monday.

  • In their June 25 lawsuit, Yale University's Global Health Justice Partnership and the Treatment Action Group, an AIDS non-profit, said doctors and patients deserve more information about the "enormously costly" drugs Harvoni and Sovaldi to make informed decisions about whether to use them. The plaintiffs said Gilead ignored its request for the trial data,...

  • AMAG buying Cord Blood Registries for $700 million Monday, 29 Jun 2015 | 10:25 AM ET

    NEW YORK— AMAG Pharmaceuticals Inc. is buying the stem-cell storage company Cord Blood Registry for $700 million from private equity firm GTCR. Waltham, Massachusetts- based AMAG focuses on specialty drugs for maternal health and anemia. Cord Blood Registry had revenue of about $126 million in 2014, the company said.

  • June 29- Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The American Diabetes Association estimates that as many as 1 in 3 American adults will have type 2 diabetes by 2050.. Still, through Friday's close of $15.19, Vitae's shares have almost...

  • June 29- Egalet Corp said data showed its experimental painkiller was less likely to be abused than a form of morphine already being sold. A study showed recreational opioid users did not like and were less prone to snort the company's painkiller, Egalet -001, than MS Contin. Egalet's study results come a week before a panel of experts advising the U.S. Food and...

  • June 29- Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The drug, being co-developed with German drugmaker Boehringer Ingelheim, was tested as an add-on therapy to metformin, a commonly prescribed diabetes drug. Results from another trial...

  • Bristol-Myers to stop new antiviral drug research Thursday, 25 Jun 2015 | 11:08 AM ET

    June 25- Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said a research facility is expected to open in Cambridge, Massachusetts in 2018 and that the expansion of an R&D site in San Francisco Bay Area is likely to be completed by 2016.. Bristol-Myers' stock was up marginally at...

  • Bristol-Myers Squibb to shift research jobs Thursday, 25 Jun 2015 | 10:59 AM ET

    HARTFORD, Conn.— Bristol-Myers Squibb Co. will expand its presence in research centers in Cambridge, Massachusetts, and San Francisco, as it cuts jobs in Connecticut, the biopharmaceutical company announced Thursday. The New York- based company will open a research site in Cambridge— home to the Massachusetts Institute of Technology and Harvard— in 2018 and...

  • Health care stocks surge as investors cheer ruling Thursday, 25 Jun 2015 | 10:42 AM ET
    Protesters outside the Supreme Court on March 4, 2015.

    See how major health care industry stocks are responding to the Supreme Court's Obamacare ruling.

  • INDIANAPOLIS— Eli Lilly received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug. Shares of the Indianapolis drugmaker climbing in premarket trading. Alimta brought in $2.79 billion in sales globally last year as...

  • Panel gives weak endorsement of new meningitis shots Wednesday, 24 Jun 2015 | 12:44 PM ET

    NEW YORK— A federal panel gave a weak endorsement Wednesday to two expensive meningitis shots, declining to recommend that all teens get the vaccine and leaving the decision to parents and doctors. At a meeting in Atlanta, the panel approved a half-measure that says older teens and young adults may get the shots— if they and their parents want to take that step.

  • June 24- AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study. All the patients in the study showed a sustained response to Viekira Pak as a standalone treatment after 12 weeks...

  • AbbVie hepatitis C cocktail succeeds in late-stage study Wednesday, 24 Jun 2015 | 6:19 AM ET

    June 24- AbbVie Inc said on Wednesday that all patients in a late-stage study showed a sustained response to its cocktail of hepatitis C treatments, currently sold in the U.S. as Viekira Pak.

  • June 23- Medtronic Inc said it was recalling certain lots of its of its tracheostomy tubes, devices used to ease breathing, after receiving complaints, including reports of 12 serious injuries. The medical device maker said it began notifying hospitals and distributors on May 8 that affected lots of its Covidien Shiley tracheostomy tubes were formed with a...